Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person's susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables, which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit vulnerable patients.

Introduction Antibiotic resistance is one of the greatest problems facing the 21st century with few new classes of antibiotics being discovered. The forefront of antibiotic discovery has been the soil microbiome and it is still a valuable resource for identifying microbes with possible antibiotic producing capabilities leading to novel classes of antibiotics. This justifies continuing investigation into the soil microbiome for antibiotic producing bacteria, to help tackle the growing trend in antibiotic resistance. A bacterial soil isolate was found to inhibit Enterococcus faecalis ATCC 29212 and the aim of this work was to further characterise the inhibition profile of the antibacterial. Methods Bacterial plug and supernatant assays were used to access the inhibition ability of a soil bacterial isolate against the WHO ‘priority pathogens’. Identification of the bacteria was carried out using 16S rRNA and whole genome sequencing. Synergy tests were carried out using broth dilution assays. Results The soil isolate (N5) was identified as Enterococcus and showed antibacterial activity against Staphylococcus aureus MRSA and E. faecalis VanA. This antibacterial is secreted into the supernatant which still showed inhibitory activity against MRSA and VRE. Synergy with N5 and ciprofloxacin (0.2  µg ml−1) against E. faecalis ATCC 29212 was also observed. Conclusion Both VRE and MRSA are important players in nosocomial infections and are displaying high levels of resistance. Further study of this antibacterial could lead to the development of a new compound to help overcome resistance mechanisms or a novel antimicrobial.

No abstract

Introduction The FunHoMic project is a Marie Skłodowska-Curie Innovative Training Network comprising 13 PhD students, 8 academic partners and 3 industry partnersaimingto understand the interplay between fungi, hostsand microbiota to improve prevention and treatment of fungal infections. Importance About 2 billion people suffer fungal infections, which have a mortality rate close to that of malaria or breast cancer. Candida albicans has a high clinical and economic burden, making it of particular interest to the FunHoMic project. 70% of women experience at least one episode of vulvovaginal candidiasis (“thrush”) during their lifetime; 8% suffer recurring infections. C. albicans may live as a commensal but can cause symptoms when the fungus-host-microbiota equilibrium is disrupted. Infections by C. albicans have a significant clinical impact, with fatalities in severe cases. Many factors are associated with C. albicans infections; intensive care, neutropenic and diabetic patients are most at risk of systemic infection. Rising antifungal drug resistance has led to certain C. albicans infections having no treatment option. Aim The FunHoMic consortium combines projectson fungal pathogenesis, immunology, microbial ecology and’omics technologies to understand and exploit interactions between fungus, host and microbiota. Identification of novel bio markers on the fungal side such as genetic polymorphisms or on the host side such asmicrobiota profiles, metabolites and/or immune markers can lead to patient classification based on relative risk of infection. This could be the beginning of personalised management for fungal infections using preventive or therapeutic interventions like new antifungals, immune modulators or Live Biotherapeutic Products (LBPs). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the MarieSklodowska-Curie grant agreement No 812969.